Willingness to pay for inhaled insulin : A contingent valuation approach
To determine the willingness to pay (WTP) of patients with diabetes mellitus for inhaled insulin. A contingent valuation survey was administered to 96 diabetic outpatients at St. Michael's Hospital, Toronto, Canada. Standardised information about inhaled insulin and subcutaneous rapid-acting in...
Gespeichert in:
| Veröffentlicht in: | PharmacoEconomics 2005-01, Vol.23 (12), p.1215-1227 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1227 |
|---|---|
| container_issue | 12 |
| container_start_page | 1215 |
| container_title | PharmacoEconomics |
| container_volume | 23 |
| creator | SADRI, Hamid MACKEIGAN, Linda D LEITER, Lawrence A EINARSON, Thomas R |
| description | To determine the willingness to pay (WTP) of patients with diabetes mellitus for inhaled insulin.
A contingent valuation survey was administered to 96 diabetic outpatients at St. Michael's Hospital, Toronto, Canada. Standardised information about inhaled insulin and subcutaneous rapid-acting insulin was provided via video. Participants' WTP for their preferred product was elicited in Canadian dollars (Can dollars) using a 'payment-scale' method.
The mean age of participants was 51.8 years (SD 13.4). Seventy-seven patients had type 2 and 19 had type 1 diabetes. Significantly more participants preferred inhaled insulin over subcutaneous insulin (85 vs 11; p < 0.01). Mean monthly WTP for inhaled insulin (153.70 Can dollars, SD 99.90) was significantly more than the typical 50 Can dollars per month for subcutaneous insulin (p < 0.01). Significantly more participants with type 2 diabetes using oral drugs than those with type 1 diabetes and using insulin preferred inhaled insulin (98.5% vs 69%, p < 0.001). Diabetic patients who did not use insulin were willing to pay significantly more than were insulin users (p < 0.001). Multiple regression analysis showed that income was significantly associated with WTP for inhaled insulin.
Diabetic patients, particularly those who are not using insulin, indicated that they would prefer inhaled insulin over insulin injection and would be willing to pay a substantial amount per month to use it. An economic evaluation of inhaled insulin would provide important information to healthcare policy decision makers and private payers about its economic value. |
| doi_str_mv | 10.2165/00019053-200523120-00006 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_68884757</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A200845747</galeid><sourcerecordid>A200845747</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-2e0b15dc0e2a424d1082da7e7157366b9e8f6548ea9ccdfbb3b3bcea3256fd2c3</originalsourceid><addsrcrecordid>eNptkdtu1DAQhi0EomXhFZAlBHdpfYjthLtVBbRSK25acWk5zqQx5ISdFO3bM9ndtkJClj2jyfeP4_kJoZydCa7VOWOMl0zJTDCmhOSCZVhi-gU55dyUWBbm5T5nmdElOyFvUvq5EtKI1-SEayk14_qUXP4IXReG-wFSovNIJ7ejzRhpGFrXQY0xLfidfqZb6sdhRhSGmT64bnFzGAfqpimOzrdvyavGdQneHeOG3H39cntxmV1__3Z1sb3OfK70nAlgFVe1ZyBcLvKas0LUzoDhykitqxKKRqu8AFd6XzdVJXF5cFIo3dTCyw35dOiL1_5eIM22D8lD17kBxiVZXRRFbrDZhnw4gPf4EBuGZpyj8ytstzi2IlcmX6mz_1C4augDPhiagPV_BMVB4OOYUoTGTjH0Lu4sZ3Y1xz6aY5_MsXtzUHpzkEaYwD_p_vxqpxbwLvtgpRMSj92aoBpDwM0FHtM-4cpyIYxt5x77vT-OYql6qJ9_5OguAh-PgEvedU10gw_pmcOJ49iV_AuXzq81</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68884757</pqid></control><display><type>article</type><title>Willingness to pay for inhaled insulin : A contingent valuation approach</title><source>MEDLINE</source><source>RePEc</source><source>SpringerLink Journals - AutoHoldings</source><creator>SADRI, Hamid ; MACKEIGAN, Linda D ; LEITER, Lawrence A ; EINARSON, Thomas R</creator><creatorcontrib>SADRI, Hamid ; MACKEIGAN, Linda D ; LEITER, Lawrence A ; EINARSON, Thomas R</creatorcontrib><description>To determine the willingness to pay (WTP) of patients with diabetes mellitus for inhaled insulin.
A contingent valuation survey was administered to 96 diabetic outpatients at St. Michael's Hospital, Toronto, Canada. Standardised information about inhaled insulin and subcutaneous rapid-acting insulin was provided via video. Participants' WTP for their preferred product was elicited in Canadian dollars (Can dollars) using a 'payment-scale' method.
The mean age of participants was 51.8 years (SD 13.4). Seventy-seven patients had type 2 and 19 had type 1 diabetes. Significantly more participants preferred inhaled insulin over subcutaneous insulin (85 vs 11; p < 0.01). Mean monthly WTP for inhaled insulin (153.70 Can dollars, SD 99.90) was significantly more than the typical 50 Can dollars per month for subcutaneous insulin (p < 0.01). Significantly more participants with type 2 diabetes using oral drugs than those with type 1 diabetes and using insulin preferred inhaled insulin (98.5% vs 69%, p < 0.001). Diabetic patients who did not use insulin were willing to pay significantly more than were insulin users (p < 0.001). Multiple regression analysis showed that income was significantly associated with WTP for inhaled insulin.
Diabetic patients, particularly those who are not using insulin, indicated that they would prefer inhaled insulin over insulin injection and would be willing to pay a substantial amount per month to use it. An economic evaluation of inhaled insulin would provide important information to healthcare policy decision makers and private payers about its economic value.</description><identifier>ISSN: 1170-7690</identifier><identifier>EISSN: 1179-2027</identifier><identifier>DOI: 10.2165/00019053-200523120-00006</identifier><identifier>PMID: 16336016</identifier><language>eng</language><publisher>Auckland: Adis International</publisher><subject>Administration, Inhalation ; Administration, Oral ; Adult ; Biological and medical sciences ; Canada ; Contingent-valuation ; Diabetes Mellitus, Type 1 - diagnosis ; Diabetes Mellitus, Type 1 - drug therapy ; Diabetes Mellitus, Type 2 - diagnosis ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes-mellitus ; Diabetes. Impaired glucose tolerance ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Female ; Financing, Personal - statistics & numerical data ; Financing, Personal - trends ; General and cellular metabolism. Vitamins ; Glyburide - administration & dosage ; Glyburide - economics ; Glyburide - therapeutic use ; Health Care Surveys - methods ; Health technology assessment ; Humans ; Hypoglycemic Agents - administration & dosage ; Hypoglycemic Agents - economics ; Hypoglycemic Agents - therapeutic use ; Inhalation ; Insulin ; Insulin - administration & dosage ; Insulin - economics ; Insulin - therapeutic use ; Male ; Medical sciences ; Metformin - administration & dosage ; Metformin - economics ; Metformin - therapeutic use ; Middle Aged ; Patient Satisfaction ; Pharmacology. Drug treatments ; Reproducibility of Results ; Subcutaneous ; Time Factors ; Willingness-to-pay</subject><ispartof>PharmacoEconomics, 2005-01, Vol.23 (12), p.1215-1227</ispartof><rights>2006 INIST-CNRS</rights><rights>COPYRIGHT 2005 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c456t-2e0b15dc0e2a424d1082da7e7157366b9e8f6548ea9ccdfbb3b3bcea3256fd2c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,3994,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17361575$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16336016$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://econpapers.repec.org/article/wkhphecon/v_3a23_3ay_3a2005_3ai_3a12_3ap_3a1215-1227.htm$$DView record in RePEc$$Hfree_for_read</backlink></links><search><creatorcontrib>SADRI, Hamid</creatorcontrib><creatorcontrib>MACKEIGAN, Linda D</creatorcontrib><creatorcontrib>LEITER, Lawrence A</creatorcontrib><creatorcontrib>EINARSON, Thomas R</creatorcontrib><title>Willingness to pay for inhaled insulin : A contingent valuation approach</title><title>PharmacoEconomics</title><addtitle>Pharmacoeconomics</addtitle><description>To determine the willingness to pay (WTP) of patients with diabetes mellitus for inhaled insulin.
A contingent valuation survey was administered to 96 diabetic outpatients at St. Michael's Hospital, Toronto, Canada. Standardised information about inhaled insulin and subcutaneous rapid-acting insulin was provided via video. Participants' WTP for their preferred product was elicited in Canadian dollars (Can dollars) using a 'payment-scale' method.
The mean age of participants was 51.8 years (SD 13.4). Seventy-seven patients had type 2 and 19 had type 1 diabetes. Significantly more participants preferred inhaled insulin over subcutaneous insulin (85 vs 11; p < 0.01). Mean monthly WTP for inhaled insulin (153.70 Can dollars, SD 99.90) was significantly more than the typical 50 Can dollars per month for subcutaneous insulin (p < 0.01). Significantly more participants with type 2 diabetes using oral drugs than those with type 1 diabetes and using insulin preferred inhaled insulin (98.5% vs 69%, p < 0.001). Diabetic patients who did not use insulin were willing to pay significantly more than were insulin users (p < 0.001). Multiple regression analysis showed that income was significantly associated with WTP for inhaled insulin.
Diabetic patients, particularly those who are not using insulin, indicated that they would prefer inhaled insulin over insulin injection and would be willing to pay a substantial amount per month to use it. An economic evaluation of inhaled insulin would provide important information to healthcare policy decision makers and private payers about its economic value.</description><subject>Administration, Inhalation</subject><subject>Administration, Oral</subject><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Canada</subject><subject>Contingent-valuation</subject><subject>Diabetes Mellitus, Type 1 - diagnosis</subject><subject>Diabetes Mellitus, Type 1 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - diagnosis</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes-mellitus</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Female</subject><subject>Financing, Personal - statistics & numerical data</subject><subject>Financing, Personal - trends</subject><subject>General and cellular metabolism. Vitamins</subject><subject>Glyburide - administration & dosage</subject><subject>Glyburide - economics</subject><subject>Glyburide - therapeutic use</subject><subject>Health Care Surveys - methods</subject><subject>Health technology assessment</subject><subject>Humans</subject><subject>Hypoglycemic Agents - administration & dosage</subject><subject>Hypoglycemic Agents - economics</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Inhalation</subject><subject>Insulin</subject><subject>Insulin - administration & dosage</subject><subject>Insulin - economics</subject><subject>Insulin - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metformin - administration & dosage</subject><subject>Metformin - economics</subject><subject>Metformin - therapeutic use</subject><subject>Middle Aged</subject><subject>Patient Satisfaction</subject><subject>Pharmacology. Drug treatments</subject><subject>Reproducibility of Results</subject><subject>Subcutaneous</subject><subject>Time Factors</subject><subject>Willingness-to-pay</subject><issn>1170-7690</issn><issn>1179-2027</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>X2L</sourceid><recordid>eNptkdtu1DAQhi0EomXhFZAlBHdpfYjthLtVBbRSK25acWk5zqQx5ISdFO3bM9ndtkJClj2jyfeP4_kJoZydCa7VOWOMl0zJTDCmhOSCZVhi-gU55dyUWBbm5T5nmdElOyFvUvq5EtKI1-SEayk14_qUXP4IXReG-wFSovNIJ7ejzRhpGFrXQY0xLfidfqZb6sdhRhSGmT64bnFzGAfqpimOzrdvyavGdQneHeOG3H39cntxmV1__3Z1sb3OfK70nAlgFVe1ZyBcLvKas0LUzoDhykitqxKKRqu8AFd6XzdVJXF5cFIo3dTCyw35dOiL1_5eIM22D8lD17kBxiVZXRRFbrDZhnw4gPf4EBuGZpyj8ytstzi2IlcmX6mz_1C4augDPhiagPV_BMVB4OOYUoTGTjH0Lu4sZ3Y1xz6aY5_MsXtzUHpzkEaYwD_p_vxqpxbwLvtgpRMSj92aoBpDwM0FHtM-4cpyIYxt5x77vT-OYql6qJ9_5OguAh-PgEvedU10gw_pmcOJ49iV_AuXzq81</recordid><startdate>20050101</startdate><enddate>20050101</enddate><creator>SADRI, Hamid</creator><creator>MACKEIGAN, Linda D</creator><creator>LEITER, Lawrence A</creator><creator>EINARSON, Thomas R</creator><general>Adis International</general><general>Springer Healthcare | Adis</general><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>DKI</scope><scope>X2L</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20050101</creationdate><title>Willingness to pay for inhaled insulin : A contingent valuation approach</title><author>SADRI, Hamid ; MACKEIGAN, Linda D ; LEITER, Lawrence A ; EINARSON, Thomas R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-2e0b15dc0e2a424d1082da7e7157366b9e8f6548ea9ccdfbb3b3bcea3256fd2c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Administration, Inhalation</topic><topic>Administration, Oral</topic><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Canada</topic><topic>Contingent-valuation</topic><topic>Diabetes Mellitus, Type 1 - diagnosis</topic><topic>Diabetes Mellitus, Type 1 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - diagnosis</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes-mellitus</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Female</topic><topic>Financing, Personal - statistics & numerical data</topic><topic>Financing, Personal - trends</topic><topic>General and cellular metabolism. Vitamins</topic><topic>Glyburide - administration & dosage</topic><topic>Glyburide - economics</topic><topic>Glyburide - therapeutic use</topic><topic>Health Care Surveys - methods</topic><topic>Health technology assessment</topic><topic>Humans</topic><topic>Hypoglycemic Agents - administration & dosage</topic><topic>Hypoglycemic Agents - economics</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Inhalation</topic><topic>Insulin</topic><topic>Insulin - administration & dosage</topic><topic>Insulin - economics</topic><topic>Insulin - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metformin - administration & dosage</topic><topic>Metformin - economics</topic><topic>Metformin - therapeutic use</topic><topic>Middle Aged</topic><topic>Patient Satisfaction</topic><topic>Pharmacology. Drug treatments</topic><topic>Reproducibility of Results</topic><topic>Subcutaneous</topic><topic>Time Factors</topic><topic>Willingness-to-pay</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SADRI, Hamid</creatorcontrib><creatorcontrib>MACKEIGAN, Linda D</creatorcontrib><creatorcontrib>LEITER, Lawrence A</creatorcontrib><creatorcontrib>EINARSON, Thomas R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>RePEc IDEAS</collection><collection>RePEc</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>PharmacoEconomics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SADRI, Hamid</au><au>MACKEIGAN, Linda D</au><au>LEITER, Lawrence A</au><au>EINARSON, Thomas R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Willingness to pay for inhaled insulin : A contingent valuation approach</atitle><jtitle>PharmacoEconomics</jtitle><addtitle>Pharmacoeconomics</addtitle><date>2005-01-01</date><risdate>2005</risdate><volume>23</volume><issue>12</issue><spage>1215</spage><epage>1227</epage><pages>1215-1227</pages><issn>1170-7690</issn><eissn>1179-2027</eissn><abstract>To determine the willingness to pay (WTP) of patients with diabetes mellitus for inhaled insulin.
A contingent valuation survey was administered to 96 diabetic outpatients at St. Michael's Hospital, Toronto, Canada. Standardised information about inhaled insulin and subcutaneous rapid-acting insulin was provided via video. Participants' WTP for their preferred product was elicited in Canadian dollars (Can dollars) using a 'payment-scale' method.
The mean age of participants was 51.8 years (SD 13.4). Seventy-seven patients had type 2 and 19 had type 1 diabetes. Significantly more participants preferred inhaled insulin over subcutaneous insulin (85 vs 11; p < 0.01). Mean monthly WTP for inhaled insulin (153.70 Can dollars, SD 99.90) was significantly more than the typical 50 Can dollars per month for subcutaneous insulin (p < 0.01). Significantly more participants with type 2 diabetes using oral drugs than those with type 1 diabetes and using insulin preferred inhaled insulin (98.5% vs 69%, p < 0.001). Diabetic patients who did not use insulin were willing to pay significantly more than were insulin users (p < 0.001). Multiple regression analysis showed that income was significantly associated with WTP for inhaled insulin.
Diabetic patients, particularly those who are not using insulin, indicated that they would prefer inhaled insulin over insulin injection and would be willing to pay a substantial amount per month to use it. An economic evaluation of inhaled insulin would provide important information to healthcare policy decision makers and private payers about its economic value.</abstract><cop>Auckland</cop><pub>Adis International</pub><pmid>16336016</pmid><doi>10.2165/00019053-200523120-00006</doi><tpages>13</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1170-7690 |
| ispartof | PharmacoEconomics, 2005-01, Vol.23 (12), p.1215-1227 |
| issn | 1170-7690 1179-2027 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68884757 |
| source | MEDLINE; RePEc; SpringerLink Journals - AutoHoldings |
| subjects | Administration, Inhalation Administration, Oral Adult Biological and medical sciences Canada Contingent-valuation Diabetes Mellitus, Type 1 - diagnosis Diabetes Mellitus, Type 1 - drug therapy Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - drug therapy Diabetes-mellitus Diabetes. Impaired glucose tolerance Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Female Financing, Personal - statistics & numerical data Financing, Personal - trends General and cellular metabolism. Vitamins Glyburide - administration & dosage Glyburide - economics Glyburide - therapeutic use Health Care Surveys - methods Health technology assessment Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - economics Hypoglycemic Agents - therapeutic use Inhalation Insulin Insulin - administration & dosage Insulin - economics Insulin - therapeutic use Male Medical sciences Metformin - administration & dosage Metformin - economics Metformin - therapeutic use Middle Aged Patient Satisfaction Pharmacology. Drug treatments Reproducibility of Results Subcutaneous Time Factors Willingness-to-pay |
| title | Willingness to pay for inhaled insulin : A contingent valuation approach |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T16%3A13%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Willingness%20to%20pay%20for%20inhaled%20insulin%20:%20A%20contingent%20valuation%20approach&rft.jtitle=PharmacoEconomics&rft.au=SADRI,%20Hamid&rft.date=2005-01-01&rft.volume=23&rft.issue=12&rft.spage=1215&rft.epage=1227&rft.pages=1215-1227&rft.issn=1170-7690&rft.eissn=1179-2027&rft_id=info:doi/10.2165/00019053-200523120-00006&rft_dat=%3Cgale_proqu%3EA200845747%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68884757&rft_id=info:pmid/16336016&rft_galeid=A200845747&rfr_iscdi=true |